Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.

As part of the Multiple Myeloma Research Foundation (MMRF) immune atlas pilot project, we compared immune cells of multiple myeloma bone marrow samples from 18 patients assessed by single-cell RNA sequencing (scRNA-seq), mass cytometry (CyTOF), and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to understand the concordance of measurements among single-cell techniques. Cell type abundances are relatively consistent across the three approaches, while variations are observed in T cells, macrophages, and monocytes. Concordance and correlation analysis of cell type marker gene expression across different modalities highlighted the importance of choosing cell type marker genes best suited to particular modalities. By integrating data from these three assays, we found International Staging System stage 3 patients exhibited decreased CD4 scRNA-seq, CyTOF, and CITE-seq are increasingly used for evaluating cellular heterogeneity. Understanding their concordances is of great interest. To date, this study is the most comprehensive examination of the measurement of the immune microenvironment in multiple myeloma using the three techniques. Moreover, we identified markers predicted to be significantly associated with multiple myeloma rapid progression.

Informations de copyright

© 2022 The Authors; Published by the American Association for Cancer Research.

Déclaration de conflit d'intérêts

S.K. Kumar reports other from Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, AstraZeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium, Loxo Oncology, K36, Sanofi, ArcellX; personal fees from ncopeptides, Beigene, Antengene, GLH Pharma; and grants from Abbvie, Amgen, Allogene, AstraZeneca, BMS, Carsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, Molecular Templates outside the submitted work. H.J. Cho reports other from The Multiple Myeloma Research Foundation during the conduct of the study; grants from BMS and Takeda outside the submitted work. A.H. Rahman reports grants from Multiple Myeloma Research Foundation during the conduct of the study; grants from Celgene/BMS and personal fees from Fluidigm outside the submitted work. D. Avigan reports other from BMS, Chugai, Sanofi, Merk, and Paraexel; and grants from MMRF outside the submitted work. S. Gnjatic reports grants from Multiple Myeloma Research Foundation during the conduct of the study; grants from Regeneron, Boehringer Ingelheim, BMS, Genentech, Jannsen R&D, Takeda, and EMD Serono outside the submitted work. No disclosures were reported by the other authors.